Investor Presentaiton

Advancing Therapy Selection with Smart Liquid Biopsy Gyn 14% Research CRC Pipeline 5% Lung 17% Gyn 10% RCC 12% 22K Samples Across >10 Indications Breast 14% Prostate 17% GUARDANT™ Internal data as of September 1, 2023 Lung 20% Multiple 17% Breast 24% Spanning 6,500 Patients Multiple 21% Prostate 17% INVESTOR 20 DAY 23 57

View entire presentation